The White House is lobbying Congress for a reprieve from a ban it approved last year on potent intoxicating hemp products, NYT reports

The White House is lobbying Congress for a reprieve from a ban it approved last year on potent intoxicating hemp products, NYT reports.

Reversals of recently enacted prohibitions via lobbying of the originating legislature follow a familiar pattern: the change typically comes through amendment language attached to a larger vehicle rather than a standalone bill, so the operative tells are committee markups and appropriations riders rather than floor debate. The administration seeking relief from a ban it itself approved signals that industry pressure and enforcement-practicality arguments have gained traction internally, a sequence seen in prior episodes where intoxicating hemp derivatives sat in a gap between farm bill legality and controlled substance law. The case distinction that matters is between a full repeal, which restores the prior market, and a reworking toward potency caps or a regulated framework, which splits the sector into compliant and non-compliant product lines. Equity exposure concentrates in the cannabis and hemp-adjacent complex, where names have historically traded on the delta between state-level patchwork and federal posture. Worth watching is whether congressional champions emerge and whether any counter-lobby from public health or state attorneys general materialises, since that has determined the fate of comparable carve-outs. Single-source reporting at this stage leaves the outcome dependent on confirmation of the legislative vehicle.